Medical Therapy of Advanced Gastrointestinal Stromal Tumor Toshirou Nishida 1 1Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan Keyword: 分子標的治療 , c-kit遺伝子 , PDGFRα遺伝子 , imatinib , sunitinib pp.194-198
Published Date 2008/2/25
DOI https://doi.org/10.11477/mf.1403101274
  • Abstract
  • Look Inside
  • Reference
  • Cited by

 The primary therapeutic choice for advanced, metastatic and/or recurrent gastrointestinal stromal tumor(GIST)is an oral intake of 400 mg/day imatinib mesylate. Advanced GIST has shown good responses to imatinib(response rate:40~60%;disease control rate:more than 80%). Responses to imatinib are considered to be well reflected by FDG-PET negativity and decrease in CT density after imatinib therapy. Progression free survival of patients with advanced GIST is improved to 2 years and overall survival 5 years. Imatinib-resistant GIST, however, is increasing as imatinib therapy is prolonged. Multidisciplinary treatment modality combined with surgery and molecular target agents is expected to overcome these phenomena.

Copyright © 2008, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院